DE69912833D1 - Zusammensetzung enthaltend sojaprotein, diätfasern und phytoestrogen sowie ihre verwendung zur vorbeugung und/oder behandlung von kardiovaskulären erkrankungen - Google Patents

Zusammensetzung enthaltend sojaprotein, diätfasern und phytoestrogen sowie ihre verwendung zur vorbeugung und/oder behandlung von kardiovaskulären erkrankungen

Info

Publication number
DE69912833D1
DE69912833D1 DE69912833T DE69912833T DE69912833D1 DE 69912833 D1 DE69912833 D1 DE 69912833D1 DE 69912833 T DE69912833 T DE 69912833T DE 69912833 T DE69912833 T DE 69912833T DE 69912833 D1 DE69912833 D1 DE 69912833D1
Authority
DE
Germany
Prior art keywords
soy protein
composition
cardiovascular diseases
phytoestroges
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69912833T
Other languages
English (en)
Other versions
DE69912833T2 (de
Inventor
Henrik Hoie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NUTRI PHARMA ASA OSLO
Original Assignee
NUTRI PHARMA ASA OSLO
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26064781&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69912833(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by NUTRI PHARMA ASA OSLO filed Critical NUTRI PHARMA ASA OSLO
Publication of DE69912833D1 publication Critical patent/DE69912833D1/de
Application granted granted Critical
Publication of DE69912833T2 publication Critical patent/DE69912833T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A23L33/11—Plant sterols or derivatives thereof, e.g. phytosterols
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/185—Vegetable proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Botany (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69912833T 1998-11-25 1999-11-25 Zusammensetzung enthaltend sojaprotein, diätfasern und phytoestrogen sowie ihre verwendung zur vorbeugung und/oder behandlung von kardiovaskulären erkrankungen Expired - Fee Related DE69912833T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA199801555 1998-11-25
DK155598 1998-11-25
DKPA199900855 1999-06-16
DK85599 1999-06-16
PCT/IB1999/001998 WO2000030665A1 (en) 1998-11-25 1999-11-25 Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of cardiovascular diseases

Publications (2)

Publication Number Publication Date
DE69912833D1 true DE69912833D1 (de) 2003-12-18
DE69912833T2 DE69912833T2 (de) 2004-09-23

Family

ID=26064781

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69912833T Expired - Fee Related DE69912833T2 (de) 1998-11-25 1999-11-25 Zusammensetzung enthaltend sojaprotein, diätfasern und phytoestrogen sowie ihre verwendung zur vorbeugung und/oder behandlung von kardiovaskulären erkrankungen

Country Status (11)

Country Link
US (1) US6630178B1 (de)
EP (1) EP1133308B1 (de)
JP (1) JP2002530347A (de)
AT (1) ATE253925T1 (de)
AU (1) AU767245B2 (de)
BR (1) BR9915687A (de)
CA (1) CA2352585A1 (de)
DE (1) DE69912833T2 (de)
HK (1) HK1041635A1 (de)
NZ (1) NZ511812A (de)
WO (1) WO2000030665A1 (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2368784A1 (en) 1999-04-20 2000-10-26 William J. Banz Methods of treating clinical diseases with isoflavones
US6544566B1 (en) 1999-04-23 2003-04-08 Protein Technologies International, Inc. Composition containing plant sterol, soy protein and isoflavone for reducing LDL cholesterol
AU779014B2 (en) * 1999-04-23 2005-01-06 Archer-Daniels-Midland Company Composition for and method of reducing low density lipoprotein cholesterol concentration
US7285297B1 (en) 1999-04-23 2007-10-23 Archer-Daniels-Midland Company Method of reducing low density liproprotein cholesterol concentration
US20020160060A1 (en) * 1999-04-26 2002-10-31 Mandy Kim Chen Enriched spreads
AU4402600A (en) * 1999-05-18 2000-12-05 Rawlings, Anthony V. Fat containing products
KR20030005280A (ko) 2000-04-14 2003-01-17 마아즈, 인코오포레이티드 혈관의 건강을 개선하기 위한 조성물과 방법
US6541522B2 (en) 2000-08-16 2003-04-01 Insmed Incorporated Methods of using compositions containing hypotriglyceridemically active stilbenoids
US6933291B2 (en) 2000-12-01 2005-08-23 N.V. Nutricia Cholesterol lowering supplement
AUPR255401A0 (en) * 2001-01-16 2001-02-08 Novogen Research Pty Ltd Regulation of lipids and/or bone density and compositions therefor
EP1357807B1 (de) 2001-02-09 2007-03-14 Unilever N.V. Nahrungsmittel enthaltend sojaprotein und statin
FI115192B (fi) * 2001-02-26 2005-03-31 Oriola Oy Funktionaalinen elintarvike ja sen valmistusmenetelmä
EP1368024A4 (de) * 2001-03-16 2009-03-18 Novogen Res Pty Ltd Behandlung von restenose
FI113612B (fi) * 2001-04-25 2004-05-31 Moshe Meidan Funktionaalinen elintarvike ja menetelmä sen valmistamiseksi
DE60219307T2 (de) * 2001-06-12 2008-01-10 Galephar M/F Oral anzuwendende arzneizusammensetzung enthaltend ein statinderivat
EP1443946A2 (de) * 2001-07-03 2004-08-11 Nutri Pharma ASA Soja-enthaltende zusammensetzung und deren verwendung zur prävention und/oder behandlung von verschiedenen krankheiten
US6787151B2 (en) * 2001-08-10 2004-09-07 Lipton, Division Of Conopco, Inc. Composition for lowering blood cholesterol
GB0125662D0 (en) * 2001-10-26 2001-12-19 Chapman Thomas B Formultion
FI20012553A0 (fi) 2001-12-21 2001-12-21 Raisio Benecol Oy Syötävät koostumukset
WO2003070006A1 (en) * 2002-02-22 2003-08-28 Nutri Pharma Asa Bread comprising soy protein
WO2003070018A2 (en) * 2002-02-22 2003-08-28 Nutri Pharma Asa Food products comprising soy protein
EP1480525A2 (de) * 2002-02-23 2004-12-01 Nutri Pharma ASA Neue sojaproteinprodukte
US20030166614A1 (en) * 2002-03-01 2003-09-04 Harrison Stanley F. Method for reducing cholesterol and triglycerides
JP2006504409A (ja) * 2002-07-24 2006-02-09 チルドレンズ　ホスピタル　メディカル　センター 鏡像異性のエクオールを含有する組成物および製品、およびその製造方法
US20040022876A1 (en) * 2002-07-30 2004-02-05 Nancy Green Cardiovascular health enhancement with soy fortified citrus juice compositions
US20040109922A1 (en) * 2002-08-21 2004-06-10 Thai Huy Lam Fruit sponge
MD2518G2 (ro) * 2003-12-09 2005-06-30 Элеонора ВАТАМАН Preparat medicamentos pentru reducerea concentratiei colesterolului in sange
EP2056226A1 (de) * 2004-01-16 2009-05-06 PM-International AG Diätetisches Lebensmittel
US7572805B2 (en) 2004-07-14 2009-08-11 Bristol-Myers Squibb Company Pyrrolo(oxo)isoquinolines as 5HT ligands
BRPI0513939A (pt) * 2004-08-23 2008-05-20 Unilever Nv composição, formador de creme e/ou clareador, composição de alimento, processo para a manufatura de uma composição e uso de uma composição
US7517991B2 (en) 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
US7368458B2 (en) 2005-01-12 2008-05-06 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
WO2006076568A2 (en) 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Thiazolopyridines as cannabinoid receptor modulators
WO2006076598A2 (en) 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
WO2006078697A1 (en) 2005-01-18 2006-07-27 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
WO2006086464A2 (en) 2005-02-10 2006-08-17 Bristol-Myers Squibb Company Dihydroquinazolinones as 5ht modulators
US20060280840A1 (en) * 2005-05-24 2006-12-14 Robertson Marion G Universal protein formulation meeting multiple dietary needs for optimal health and enhancing the human immune system
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
US7629342B2 (en) 2005-06-17 2009-12-08 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
TW200726765A (en) 2005-06-17 2007-07-16 Bristol Myers Squibb Co Triazolopyridine cannabinoid receptor 1 antagonists
US7317012B2 (en) 2005-06-17 2008-01-08 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoind-1 receptor modulators
US7632837B2 (en) 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
US7795436B2 (en) 2005-08-24 2010-09-14 Bristol-Myers Squibb Company Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
AR056155A1 (es) 2005-10-26 2007-09-19 Bristol Myers Squibb Co Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica
TW200729300A (en) * 2005-11-30 2007-08-01 Nuflare Technology Inc Film-forming method and film-forming equipment
US7553836B2 (en) 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
US8110231B2 (en) * 2006-04-10 2012-02-07 Kraft Foods Global Brands Llc Methods for making improved texture cereal bars
US8598111B2 (en) 2006-09-15 2013-12-03 Soy Labs, Llc Products and methods using soy peptides to lower total and LDL cholesterol levels
JP5500989B2 (ja) 2006-09-16 2014-05-21 ソイ ラブズ エルエルシー 総コレステロールおよびｌｄｌコレステロール値を低下させる大豆ペプチドを用いる生成物および方法
US9101161B2 (en) * 2006-11-02 2015-08-11 The Coca-Cola Company High-potency sweetener composition with phytoestrogen and compositions sweetened therewith
ES2861301T3 (es) 2007-06-13 2021-10-06 Otsuka Pharma Co Ltd Gelatina y bebida que contienen equol
US20090011994A1 (en) 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
PE20091928A1 (es) 2008-05-29 2009-12-31 Bristol Myers Squibb Co Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
EA201101231A1 (ru) 2009-03-27 2012-06-29 Бристол-Майерс Сквибб Компани Способы предотвращения или снижения риска смертности
TWI426915B (zh) 2010-12-29 2014-02-21 Univ Nat Pingtung Sci & Tech 台灣藜用以製備治療高血脂症及高膽固醇症之藥物的用途及其醫藥組成物
US9586900B2 (en) 2012-09-05 2017-03-07 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
EP2892897A1 (de) 2012-09-05 2015-07-15 Bristol-Myers Squibb Company Pyrrolon- oder pyrrolidinon-antagonisten des melaninkonzentrierenden hormonrezeptor-1
US20160015776A1 (en) 2013-03-15 2016-01-21 Soy Labs, Llc Products and methods using lunasin enriched soy extract mixtures to reduce free fatty acid levels, increase leptin levels and increase adiponectin levels in plasma
WO2015148384A1 (en) 2014-03-26 2015-10-01 Abbott Laboratories Nutritional supplement powder
USD767244S1 (en) 2015-09-03 2016-09-27 The J.M. Smucker Company Coated food product
USD767243S1 (en) 2015-09-03 2016-09-27 The J.M. Smucker Company Coated food product
USD767241S1 (en) 2015-09-03 2016-09-27 The J.M. Smucker Company Coated food product
USD767242S1 (en) 2015-09-03 2016-09-27 The J.M Smucker Company Coated food product
WO2017151540A1 (en) 2016-02-29 2017-09-08 Abbott Laboratories Nutritional supplement powder
AU2019304032B2 (en) 2018-07-19 2021-12-09 Astrazeneca Ab Methods of treating HFpEF employing dapagliflozin and compositions comprising the same
WO2021064107A1 (en) 2019-10-02 2021-04-08 Norvia Nutrition Ltd. Composition comprising soy and use thereof in the prevention and/or treatment of microvascular or lipoprotein related diseases, microcardiovascular diseases, atherosclerosis, hypertension, and in patients with such cardiovascular disorders suffering from alzheimer and dementia, overweight and obesity, type 2 diabetes, asthma and other disorders
WO2023212130A1 (en) * 2022-04-28 2023-11-02 GreenStone Biosciences, Inc. Treatment of the adverse cardiovascular effects of cannabinoids

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2395288A1 (fr) * 1977-06-23 1979-01-19 Ppn Nouvelles compositions therapeutiques destinees notamment a la prevention et au traitement des maladies de plethore
US4557927A (en) 1983-03-10 1985-12-10 Kabushiki Kaisha Hoyashibara Food products and process for producing same
FR2543550B1 (fr) 1983-04-01 1985-08-09 Cortial Nouveaux derives de la tetrahydroxy-3', 4',5,7 flavone, leur methode de preparation et leur emploi therapeutique
JPS62201882A (ja) 1985-11-18 1987-09-05 Yamanouchi Pharmaceut Co Ltd イソフラボン誘導体
US4818558A (en) 1987-08-04 1989-04-04 Worthington Foods, Inc. Fiber/tofu food product and method for making the same
JPH0714927B2 (ja) 1988-04-06 1995-02-22 キッコーマン株式会社 イソフラボン化合物の製造法
ATE275959T1 (de) 1992-05-19 2004-10-15 Graham Edmund Kelly Verwendung von isoflavon phyto-östrogen extrakten von soja oder klee
DK171752B1 (da) 1992-07-06 1997-05-12 Birgitte Stilling Brødlignende produkt med blodsukkersænkende virkning til diabetikere samt pulverformig blanding til anvendelse ved fremstilling deraf
WO1994023716A1 (en) 1993-04-16 1994-10-27 Tufts University School Of Medicine Method for treatment of menopausal and premenstrual symptoms
US5320949A (en) 1993-10-12 1994-06-14 Protein Technologies International, Inc. Process for producing aglucone isoflavone enriched vegetable protein fiber
US6140469A (en) 1993-10-12 2000-10-31 Protein Technologies International, Inc. Protein isolate having an increased level of isoflavone compounds and process for producing the same
JP3777389B2 (ja) 1993-10-12 2006-05-24 アーチャー ダニエルズ ミッドランド カンパニー アグルコンイソフラボン濃縮植物タンパク質濃縮物及びその製造方法
WO1995010530A1 (en) 1993-10-12 1995-04-20 Protein Technologies International, Inc. An aglucone isoflavone enriched vegetable protein extract and isolate and process for producing
EP0723536B2 (de) 1993-10-12 2006-06-14 Archer Daniels Midland Company Ein aglucon isoflavon angereichertes pflanzliches molkeprotein, und ein verfahren zur herstellung
CN1102991A (zh) * 1993-11-24 1995-05-31 李良云 纯天然减肥保健饮料
US5589182A (en) 1993-12-06 1996-12-31 Tashiro; Renki Compositions and method of treating cardio-, cerebro-vascular and alzheimer's diseases and depression
US5463283A (en) 1994-05-24 1995-10-31 Bkl, Inc. Drive circuit for electroluminescent lamp
AU3689095A (en) 1994-10-03 1996-04-26 Schouten Industries B.V. Food and health products
US5516528A (en) 1995-01-13 1996-05-14 Wake Forest University Dietary phytoestrogen in estrogen replacement therapy
IL115110A (en) 1995-08-30 1997-08-14 Chajuss Daniel Soy molasses
DE902624T1 (de) * 1996-02-29 2000-11-02 Nutri Pharma Asa, Oslo Zusammensetzung, die als nahrungsmittel oder zur senkung des serumlipidspiegels geeignet ist
US5702752A (en) 1996-03-13 1997-12-30 Archer Daniels Midland Company Production of isoflavone enriched fractions from soy protein extracts
ATE222064T1 (de) 1996-04-09 2002-08-15 Du Pont Isoflavon angereichertes sojaeiweissprodukt und verfahren zur herstellung
TW425285B (en) * 1996-06-10 2001-03-11 Viva America Marketing Inc Fish oil and garlic nutritive supplement
AU3887597A (en) * 1996-07-18 1998-02-10 Nutricor, Inc. Nutritious food preparations and methods for making them
US5654011A (en) 1996-07-30 1997-08-05 Energetics, Inc. Dietary supplements
US5726034A (en) 1996-09-06 1998-03-10 Protein Technologies International, Inc. Aglucone isoflavone enriched vegetable protein extract and protein material, and high genistein and daidzein content materials and process for producing the same
ATE362715T1 (de) 1997-06-23 2007-06-15 Nestle Sa Zusammensetzung zur ernährung von diabetikern
US5855892A (en) 1997-09-19 1999-01-05 Potter; Susan M. Method for decreasing LDL-cholesterol concentration and increasing HDL-cholesterol concentration in the blood to reduce the risk of atherosclerosis and vascular disease
CA2352338A1 (en) * 1998-11-25 2000-06-02 Nutri Pharma Asa Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of pulmonary diseases

Also Published As

Publication number Publication date
DE69912833T2 (de) 2004-09-23
NZ511812A (en) 2003-11-28
WO2000030665A1 (en) 2000-06-02
AU767245B2 (en) 2003-11-06
EP1133308B1 (de) 2003-11-12
HK1041635A1 (zh) 2002-07-19
JP2002530347A (ja) 2002-09-17
CA2352585A1 (en) 2000-06-02
BR9915687A (pt) 2001-12-04
ATE253925T1 (de) 2003-11-15
EP1133308A1 (de) 2001-09-19
AU1404700A (en) 2000-06-13
US6630178B1 (en) 2003-10-07

Similar Documents

Publication Publication Date Title
DE69912833D1 (de) Zusammensetzung enthaltend sojaprotein, diätfasern und phytoestrogen sowie ihre verwendung zur vorbeugung und/oder behandlung von kardiovaskulären erkrankungen
DE69914947D1 (de) Zusammensetzung enthaltend sojaprotein, diätfasern und phytoestrogen sowie ihre verwendung zur vorbeugung und/oder behandlung von typ ii diabetes, des metabolischen syndroms und assozierten kardiovaskulären erkrankungen
DE69908809D1 (de) Verwendung einer zusammensetzung enthaltend sojaprotein, diätfasern und phytoestrogen zur vorbeugung und/oder behandlung von lungenerkrankungen
ATE198405T1 (de) Zusammensetzung, die als nahrungsmittel oder zur senkung des serumlipidspiegels geeignet ist
CA2286655A1 (en) Tissue decellularization
DE60220145D1 (de) Verwendung eines mutterkrautextrakts zur regulierung der hautalterung
DE69822919D1 (de) Spezifische Antikörper zur Verwendung in der Herstellung pharmazeutischer Zusammensetzungen nützlich für die Vorbeugung oder Behandlung von Gastritis, Magen- und Zwölffingerdarmgeschwüren
CA2289851A1 (en) Compounds and methods for the inhibition of the expression of vcam-1
ATE86858T1 (de) Verwendung von buspiron zur herstellung von pharmazeutischen zusammensetzungen zur linderung von krankhaften angst.
ATE219073T1 (de) Benzopyran derivate mit leukotrien- antagonistischer wirkung
WO2003004039A3 (en) Composition comprising soy and use thereof in the prevention and/or treatment of various diseases
DE3586044D1 (de) Chromogene kupplungskomponente und ihre verwendung zur analytischen bestimmung von wasserstoffperoxyd oder von anderen analyten.
UA37199C2 (uk) Алкіламінокетони
EP0815868A4 (de) Eine chinesische drogen zusammensetzung zur behandlung von magengeschwüren und herstellung davon
ATE39694T1 (de) (pyrrol-1-yl)-phenyl-dihydropyridazinone, ihre herstellung und verwendung.
MY106885A (en) Use of tenidap to reduce total serum cholesterol, ldl cholesterol and triglycerides
WO2001070206A3 (en) Combination of lecithin with ascorbic acid
DE68900867D1 (de) 1,5-benzothiazepinderivate, ihre herstellung und ihre verwendung in der behandlung von kardiovasculaeren stoerungen.
CA2182157A1 (en) Composition for a Dietary Supplement for the Treatment of Hemorrhoids
He et al. Generalized Minkowski content, spectrum of fractal drums, fractal strings and the Riemann zeta-function
RU98122037A (ru) СПОСОБ ПОЛУЧЕНИЯ α-ТОКОФЕРОЛА (ВИТАМИНА Е)
ATE72813T1 (de) 1,5-benzothiazepinderivate, ihre herstellung und ihre verwendung in der behandlung von kardiovasculaeren stoerungen.
DE69933041D1 (de) Verwendung von puroindolin zur herstellung von keksen, danach erhältliche keksteige und kekse

Legal Events

Date Code Title Description
8363 Opposition against the patent
8339 Ceased/non-payment of the annual fee